New IPO in Obesity Sector: Q&A with Robert Cucin from Biosculpture Technologies

Spotlight Companies  |

Moderator for Equities Steve Kanaval spoke with Robert Cucin MD at Bioscultpure Technologies about his upcoming IPO and Capital Raise and how investors can participate. read below to learn more about the exciting news from Robert and Biosculpture. Click here to learn more about how to invest. As always Thank You for reading !!!

Equities: Robert tell me about Biosculpture, which we will call BST going forward.

BioSculpture Technology, Inc. is a commercial stage medical device manufacturer developing a patented and prototyped minimally invasive device for the endoscopic removal of visceral or “belly” fat as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. We believe our method and device will save lives, improve life outcomes, and significantly reduce healthcare costs.

Equities: Tell us about the size of the market

Robert: 2/3 of the population is overweight and 43% are forecast to be obese in the next few years. US Health reports there are 2.1 Billion people suffering from obesity around the globe and obesity costs will exceed $2 Trillion. Also know that 80% of type 2 diabetics are obese; diabetes mellitus is the leading cause of renal failure needing dialysis and a frequent cause of blindness. Obesity doesn’t just shorten your life, but it lessens the quality of it.

Equities: What is the specific market where you are having a disruptive effect.

Robert: Obesity medical device expenditures exceeded $1.4 Billion in 2014. McKinsey Global Institute forecasts the obesity market to reach $17 trillion USD by 2030. There is an enormous unmet need in developed countries and a large potential in lower income countries due to the cost-effective nature of the device for a minimally invasive treatment of obesity which is safer and highly effective. There are roughly 20M diagnosed type 2 diabetics in the U.S. alone. Diet and Exercise seldom works for the long haul.

Equities: Explain what is the revenue opportunity for you and investors

Robert: Visceral or “belly” fat not only causes sleep apnea and gastric reflux but secretes the cellular hormones that are responsible for all the complications of obesity – diabetes, hypertension, vascular disease, strokes, heart attacks, autoimmune diseases, and cancers. Patented and proprietary methods and devices have been prototyped and are being tested. We believe our device is distinct from and superior to all current or experimental therapies because there is no need to cut into the stomach or bowel, rearrange the alimentary tract, leave behind a foreign body, or be limited by a weight loss plateau. We have been granted three (3) U.S. patents ( (8,348,929B2, 8,465,471B2, 8,574,223) on both method and the device and numerous other patents are pending. Following the successful completion of the current equity offering, we expect our device to become Initially commercially available for “tissue and fluid aspiration, including body sculpting and liposuction” under a 510(k) and after regulatory approvals are obtained and clinical trials performed, subsequently to be promoted as a treatment of obesity.

Equities: The management team at smaller companies is critical, tell us about your team

Robert: I founded the Company and my training is as a Cornell-trained physician founder (see his LinkedIn Here Robert L. Cucin, M.D.) as a serial medical technology entrepreneur who invented this technology and acquired a Columbia MBA to serve as its CEO. His experience includes his being an IP attorney who has successfully licensed his early patents to companies such as Mentor and Ethicon. Its CFO, Deborah Salerno has over 25 years of experience as an investment banker in taking company public, SEC filings and PIPES. The team also has a full complement of technical, clinical and regulatory expertise.

Equities: What is you funding and exit strategy.

Robert: We have a qualified tier 2 Regulation A Offering for $5,000,000 as an active IPO and plan to apply for OTC-QB listing in Q2 2017. The use of proceeds will include completion of prototype development and obtaining preliminary FDA and European Union approvals.

In the interest of full disclosure, we call the reader's attention to the fact that, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash for market awareness services provided to this client.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Last Price Change % Change